Publication:
Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.

dc.contributor.authorSuay-Corredera, Carmen
dc.contributor.authorPricolo, Maria Rosaria
dc.contributor.authorHerrero-Galán, Elías
dc.contributor.authorVelázquez-Carreras, Diana
dc.contributor.authorSánchez-Ortiz, David
dc.contributor.authorGarcía-Giustiniani, Diego
dc.contributor.authorDelgado, Javier
dc.contributor.authorGalano-Frutos, Juan José
dc.contributor.authorGarcía-Cebollada, Helena
dc.contributor.authorVilches, Silvia
dc.contributor.authorDomínguez, Fernando
dc.contributor.authorMolina, María Sabater
dc.contributor.authorBarriales-Villa, Roberto
dc.contributor.authorFrisso, Giulia
dc.contributor.authorSancho, Javier
dc.contributor.authorSerrano, Luis
dc.contributor.authorGarcía-Pavía, Pablo
dc.contributor.authorMonserrat, Lorenzo
dc.contributor.authorAlegre-Cebollada, Jorge
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderEuropean Research Area Network on Cardiovascular Diseases
dc.contributor.funderComunidad de Madrid (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderFundación ProCNIC
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERCV (Enfermedades Cardiovasculares)
dc.contributor.funderGobierno de Aragón (España)
dc.date.accessioned2022-11-16T14:05:32Z
dc.date.available2022-11-16T14:05:32Z
dc.date.issued2021
dc.description.abstractHypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Variants in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are the leading cause of HCM. However, the pathogenicity status of hundreds of MYBPC3 variants found in patients remains unknown, as a consequence of our incomplete understanding of the pathomechanisms triggered by HCM-causing variants. Here, we examined 44 nontruncating MYBPC3 variants that we classified as HCM-linked or nonpathogenic according to cosegregation and population genetics criteria. We found that around half of the HCM-linked variants showed alterations in RNA splicing or protein stability, both of which can lead to cMyBP-C haploinsufficiency. These protein haploinsufficiency drivers associated with HCM pathogenicity with 100% and 94% specificity, respectively. Furthermore, we uncovered that 11% of nontruncating MYBPC3 variants currently classified as of uncertain significance in ClinVar induced one of these molecular phenotypes. Our strategy, which can be applied to other conditions induced by protein loss of function, supports the idea that cMyBP-C haploinsufficiency is a fundamental pathomechanism in HCM.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipFunding and additional information—J. A.-C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN) through grants BIO2014-54768-P; BIO2017-83640-P/MINECO/AEI/ FEDER, UE; EIN2019-102966 and RYC-2014-16604, the European Research Area Network on Cardiovascular Diseases (ERA-CVD/ ISCIII, Spain MINOTAUR, AC16/00045), and the Comunidad de Madrid (consortium Tec4Bio-CM, S2018/NMT-4443, FEDER). The CNIC is supported by the ISCIII, MCIN, and the Pro CNIC Foundation and was a Severo Ochoa Center of Excellence (SEV2015-0505). We acknowledge funding from ISCIII to the Centro de Investigación Biomédica en Red (CB16/11/00425). L. S. acknowledges funding from MCIN (BFU2015-63571-P). J. S. acknowledges funding from AEI (PID2019-107293GB-I00), Gobierno de Aragón (E45_17R), and ERDF-InterregV-A POCTEFA, Spain (PIREPREDEFA086/15). C. S.-C. is the recipient of an FPI-SO predoctoral fellowship BES-2016-076638. M. R. P. was the recipient of a PhD fellowship from the Italian Ministry of Education, Universities and Research, Italy. H. G.-C. is the recipient of an FPU16/04232 doctoral contract from MCIN.es_ES
dc.identifier.citationJ Biol Chem. 2021 Jul;297(1):100854es_ES
dc.identifier.doi10.1016/j.jbc.2021.100854es_ES
dc.identifier.e-issn1083-351Xes_ES
dc.identifier.journalJ Biol Chemes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15169
dc.language.isoenges_ES
dc.publisherAmerican Society of Biological Chemistses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BIO2014-54768-Pes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BIO2017-83640-Pes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/EIN2019-102966es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC-2014-16604es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/AC16/00045es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/S2018/NMT-4443es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SEV2015-0505es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CB16/11/00425es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BFU2015-63571-Pes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-107293GB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PIREPREDEFA086/15es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BES-2016-076638es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU16/04232es_ES
dc.relation.publisherversion10.1016/j.jbc.2021.100854es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Mecánica molecular del sistema cardiovasculares_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshCardiomyopathy, Hypertrophices_ES
dc.subject.meshCarrier Proteinses_ES
dc.subject.meshCytoskeletal Proteinses_ES
dc.subject.meshFemalees_ES
dc.subject.meshHaploinsufficiencyes_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.subject.meshMolecular Dynamics Simulationes_ES
dc.subject.meshMutationes_ES
dc.subject.meshPhenotypees_ES
dc.subject.meshRNA Splicinges_ES
dc.titleProtein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication0897baf7-053d-42dd-9c3b-3e6f75932138
relation.isAuthorOfPublicationc7cbbba5-033e-43e3-978e-9220b7c40875
relation.isAuthorOfPublication.latestForDiscovery0897baf7-053d-42dd-9c3b-3e6f75932138
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublication074a3e7c-5bec-4f3f-91ff-0549bfa3ad31
relation.isFunderOfPublicationc87c70a3-e023-4b6b-ac25-1b2d1b483786
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationef935eeb-4c46-446a-868e-66e905683e75
relation.isFunderOfPublication9bec53f6-b1d2-4340-9f6b-91815956d602
relation.isFunderOfPublicationd7888c6f-5c83-4168-b796-35938e852ce1
relation.isFunderOfPublicationd9081f19-60cf-4e43-b80c-5f49c2e30a4d
relation.isFunderOfPublication.latestForDiscovery289dce42-6a28-4892-b0a8-c70c46cbb185

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
J Biol Chem 2021 Protein haploinsufficiency drivers.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format
Description:
Artículo